Roth Capital Maintains Buy on Annovis Bio, Lowers Price Target to $7

Benzinga Newsdesk www.benzinga.com Negative 55.2%

Neg 55.2% Neu 0% Pos 0%

Roth Capital analyst Boobalan Pachaiyappan maintains Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $8 to $7.